IOVA - ライオン・バイオテクノロジ―ズ (Iovance Biotherapeutics Inc.) ライオン・バイオテクノロジ―ズ

 IOVAのチャート


 IOVAの企業情報

symbol IOVA
会社名 Iovance Biotherapeutics Inc (ライオン・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイオワンス・バイオセラピューティクス(Iovance Biotherapeutics Inc.)(旧名:Lion Biotechnologies Inc)は臨床段階バイオ医薬品会社である。同社は患者自身の免疫システムによって癌細胞を根絶する癌免疫療法製品の開発・商業化に従事する。同社ののリードプログラムは転移性メラノーマの治療のために患者の腫瘍に由来するT細胞である腫瘍浸潤リンパ球を利用する養子細胞療法である。同社は子宮頸癌および頭頸部癌を治療するためにLN-145を開発中である。同社は眼科用メラノーマ、膀胱癌、乳癌、肺癌などの他の固形腫瘍適応症における非改変TILを評価するために国立癌研究所と共同研究を行う。同社はチェックポイントインヒビターKeytrudaと組み合わせてTILを評価するためにNCIと協力する。  ライオン・バイオテクノロジ―ズは米国のバイオ医薬品会社。転移性黒色腫、およびその他固形腫瘍に焦点を充てた新薬の開発に注力する。転移性黒色腫、およびその他固形腫瘍治療向けに、自家腫瘍浸潤リンパ球を使用した養子免疫療法の開発と商品化を手掛ける。本社はカリフォルニア州。   Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
本社所在地 999 Skyway Road Suite 150 San Carlos CA 94070 USA
代表者氏名 Iain D. Dukes イアン・D・デュークス
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-260-7120
設立年月日 39326
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 63人
url www.lionbio.com
nasdaq_url https://www.nasdaq.com/symbol/iova
adr_tso
EBITDA EBITDA(百万ドル) -105.72800
終値(lastsale) 10.92
時価総額(marketcap) 1043866485.48
時価総額 時価総額(百万ドル) 1134.795
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 858.70200
当期純利益 当期純利益(百万ドル) -105.17800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Iovance Biotherapeutics Inc revenues was not reported. Net loss increased 30% to $57.2M. Higher net loss reflects Research and development - Balancing val increase of 21% to $40.1M (expense) General_Administrative - Balancing val increase of 81% to $8.8M (expense) Stock-based Compensation in SGA increase of 50% to $4.9M (expense).

 IOVAのテクニカル分析


 IOVAのニュース

   Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News  2020/06/25 09:55:38 Live Trading News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]
   Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?  2020/06/04 15:31:26 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know  2020/06/02 16:00:12 Zacks Investment Research
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil  2020/05/06 15:26:00 Zacks Investment Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
   Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?  2020/04/17 12:43:00 Zacks Investment Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
   Cellectis S A : Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive | Zone bourse  2020/01/12 21:02:02 Zonebourse
Iovance Biotherapeutics utilisera la technologie TALEN® de Cellectis pour le développement de TIL génétiquement modifiés … | 12 janvier 2020
   Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive  2020/01/12 21:00:00 Business Wire
SAN CARLOS, Calif. & NEW YORK--(BUSINESS WIRE)--Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive
   Iovance Biotherapeutics Inc (NASDAQ:IOVA) Expected to Announce Earnings of -$0.42 Per Share  2019/11/07 20:10:42 Modern Readers
Brokerages expect that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will announce ($0.42) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.45). Iovance Biotherapeutics posted earnings per share of ($0.27) in the same quarter last year, which […]
   The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut  2019/06/19 11:51:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.
   Cellectis S A : Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive | Zone bourse  2020/01/12 21:02:02 Zonebourse
Iovance Biotherapeutics utilisera la technologie TALEN® de Cellectis pour le développement de TIL génétiquement modifiés … | 12 janvier 2020
   Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive  2020/01/12 21:00:00 Business Wire
SAN CARLOS, Calif. & NEW YORK--(BUSINESS WIRE)--Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive
   Iovance Biotherapeutics Inc (NASDAQ:IOVA) Expected to Announce Earnings of -$0.42 Per Share  2019/11/07 20:10:42 Modern Readers
Brokerages expect that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will announce ($0.42) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.45). Iovance Biotherapeutics posted earnings per share of ($0.27) in the same quarter last year, which […]
   The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut  2019/06/19 11:51:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ライオン・バイオテクノロジ―ズ IOVA Iovance Biotherapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)